Pilot Pharmacokinetic Study in Healthy Adults Using Intravascular Microdialysis Catheters Modified for Use in Paediatric Patients to Assess Vancomycin Blood Levels.
Journal
Clinical pharmacokinetics
ISSN: 1179-1926
Titre abrégé: Clin Pharmacokinet
Pays: Switzerland
ID NLM: 7606849
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
accepted:
02
11
2022
pubmed:
6
12
2022
medline:
8
2
2023
entrez:
5
12
2022
Statut:
ppublish
Résumé
Exhaustive pharmacokinetic (PK) studies in paediatric patients are unavailable for most antibiotics and feasibility of PK studies is limited by challenges, such as low blood volume and venipuncture-related pain. Microdialysis (MD) represents a promising method to overcome these obstacles. The aim of this proof-of-concept study was to develop and validate modified MD catheters that can be used to obtain concentration-time profiles of antibiotics in paediatric patients. Following extensive in vitro MD experiments, a prospective open-labelled study in ten healthy adult volunteers (HVs) was conducted. Subjects received a single intravenous dose of 1000 mg vancomycin, then plasma and intravascular microdialysate were sampled over 24 h. In vivo MD probe calibration was conducted using the retrodialysis technique. Plasma protein binding was measured using ultrafiltration. Confirmation of the measurements was performed using a Bland-Altman plot, relevant PK parameters were calculated, and a pharmacometric model was established. No safety issues were encountered. The concentration-time curves of microdialysate and plasma measurements showed good alignment. The Bland-Altman plot yielded a mean bias of 0.19 mg/L and 95% limits of agreement of - 9.34 to 9.71 mg/L. A two-compartment model best described plasma PK, model-based estimates for recovery of the MD probes being in high agreement with the observed values. Quantified estimates of fraction unbound were comparable between plasma and microdialysate (p = 0.56). An innovative MD catheter that can be inserted into small intravenous lines was successfully developed and applied in HV. This proof-of-concept study is encouraging and opens the way to further experiments leading towards future use of MD in paediatric patients.
Sections du résumé
BACKGROUND AND OBJECTIVE
Exhaustive pharmacokinetic (PK) studies in paediatric patients are unavailable for most antibiotics and feasibility of PK studies is limited by challenges, such as low blood volume and venipuncture-related pain. Microdialysis (MD) represents a promising method to overcome these obstacles. The aim of this proof-of-concept study was to develop and validate modified MD catheters that can be used to obtain concentration-time profiles of antibiotics in paediatric patients.
METHODS
Following extensive in vitro MD experiments, a prospective open-labelled study in ten healthy adult volunteers (HVs) was conducted. Subjects received a single intravenous dose of 1000 mg vancomycin, then plasma and intravascular microdialysate were sampled over 24 h. In vivo MD probe calibration was conducted using the retrodialysis technique. Plasma protein binding was measured using ultrafiltration. Confirmation of the measurements was performed using a Bland-Altman plot, relevant PK parameters were calculated, and a pharmacometric model was established.
RESULTS
No safety issues were encountered. The concentration-time curves of microdialysate and plasma measurements showed good alignment. The Bland-Altman plot yielded a mean bias of 0.19 mg/L and 95% limits of agreement of - 9.34 to 9.71 mg/L. A two-compartment model best described plasma PK, model-based estimates for recovery of the MD probes being in high agreement with the observed values. Quantified estimates of fraction unbound were comparable between plasma and microdialysate (p = 0.56).
CONCLUSIONS
An innovative MD catheter that can be inserted into small intravenous lines was successfully developed and applied in HV. This proof-of-concept study is encouraging and opens the way to further experiments leading towards future use of MD in paediatric patients.
Identifiants
pubmed: 36471223
doi: 10.1007/s40262-022-01190-7
pii: 10.1007/s40262-022-01190-7
pmc: PMC9898326
doi:
Substances chimiques
Vancomycin
6Q205EH1VU
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
77-87Informations de copyright
© 2022. The Author(s).
Références
J Biopharm Stat. 2007;17(4):571-82
pubmed: 17613642
Antimicrob Agents Chemother. 1988 Jan;32(1):92-5
pubmed: 3279907
Eur J Pharm Sci. 2021 Feb 1;157:105607
pubmed: 33141034
Comput Methods Programs Biomed. 2005 Sep;79(3):241-57
pubmed: 16023764
J Antimicrob Chemother. 2021 Jul 15;76(8):2106-2113
pubmed: 33970263
Clin Pharmacokinet. 2019 Jan;58(1):39-52
pubmed: 29675639
J Antimicrob Chemother. 2018 Mar 1;73(3):564-568
pubmed: 29216348
J Antimicrob Chemother. 2021 Aug 12;76(9):2342-2351
pubmed: 34050650
BMJ. 2002 Mar 9;324(7337):588-91
pubmed: 11884326
Clin Biochem. 2017 May;50(7-8):418-424
pubmed: 28027888
Hosp Pediatr. 2019 Mar;9(3):186-193
pubmed: 30745323
Drug Test Anal. 2014 May;6(5):399-414
pubmed: 24692095
Pharm Res. 2004 Sep;21(9):1698-707
pubmed: 15497699
Br J Clin Pharmacol. 2015 Mar;79(3):395-404
pubmed: 25855821
Eur J Drug Metab Pharmacokinet. 2020 Aug;45(4):535-546
pubmed: 32304024
DICP. 1991 Jul-Aug;25(7-8):713-5
pubmed: 1949924
Antimicrob Agents Chemother. 2019 Apr 25;63(5):
pubmed: 30833429
J Pharmacokinet Pharmacodyn. 2020 Jun;47(3):219-228
pubmed: 32248328
N Engl J Med. 2003 Sep 18;349(12):1157-67
pubmed: 13679531
BMJ. 2000 Jan 8;320(7227):79-82
pubmed: 10625257
J Antimicrob Chemother. 2019 Apr 1;74(4):1003-1011
pubmed: 30668696
Int J Antimicrob Agents. 2021 Oct;58(4):106405
pubmed: 34289402
Clin Pharmacokinet. 2018 Jul;57(7):797-816
pubmed: 29332251